PDF(Pubmed)
Abstract：
This rapid review summarizes the latest primary research in temporomandibular joint (TMJ) injection treatment. The final literature searches were conducted on 4 January 2024. Selection was performed systematically following predefined eligibility criteria. Randomized control trials concerning the treatment of TMJ disorders with intra-articular injections were included. Studies on more invasive interventions were excluded. Quality of life, joint pain and range of mandibular mobility were assessed. Ultimately, 12 studies covering a total of 603 patients qualified. They concerned: (1) arthrocentesis (AC) and the administration of, (2) injectable platelet-rich fibrin (I-PRF), (3) platelet-rich plasma (PRP), (4) hyaluronic acid (HA), (5) non-steroidal anti-inflammatory drugs (NSAIDs), and (6) hypertonic dextrose (HD) with a local anesthetic. The dominant approach was to perform arthrocentesis before administering the appropriate injection substance (I-PRF, PRP, HA, or NSAID). Two current studies on the intra-articular administration of NSAIDs, specifically tenoxicam and piroxicam, are noteworthy. A mixture of PRP and HA was injected in another two trials. These two innovative approaches may prove to be significant directions for further research on injection treatment of TMJs.
摘要：
这篇快速综述总结了颞下颌关节（TMJ）注射治疗的最新初步研究。最终文献检索于2024年1月4日进行。根据预定的合格标准系统地进行选择。包括有关关节内注射治疗TMJ疾病的随机对照试验。排除了更多侵入性干预措施的研究。生活质量,评估关节疼痛和下颌活动度范围.最终,12项研究涵盖了总共603名合格患者。他们涉及：（1）关节穿刺术（AC）和管理，（2）可注射富血小板纤维蛋白（I-PRF），（3）富血小板血浆（PRP），（4）透明质酸（HA），（5）非甾体抗炎药（NSAIDs），和(6)使用局部麻醉剂的高渗葡萄糖(HD)。主要的方法是在施用适当的注射物质(I-PRF，PRP,HA,或NSAID)。关于NSAIDs关节内给药的两项最新研究，特别是替诺昔康和吡罗昔康，值得注意的是。在另外两个试验中注射PRP和HA的混合物。这两种创新方法可能被证明是进一步研究TMJ注射治疗的重要方向。
